Cost-effectiveness analysis of a single-inhaler triple therapy for COPD in the UK

UK management costs for COPD, estimated at £1.9 billion/year, are rising. In the FULFIL (Lung Function and Quality of Life Assessment in Chronic Obstructive Pulmonary Disease with Closed Triple Therapy) study, single-inhaler triple therapy with fluticasone furoate/umeclidinium/vilanterol (100/62.5/2...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenwick, Elisabeth, Martin, Alan, Schroeder, Melanie, Mealing, Stuart J., Solanke, Oyinkansola, Risebrough, Nancy, Ismaila, Afisi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983252/
https://www.ncbi.nlm.nih.gov/pubmed/33778055
http://dx.doi.org/10.1183/23120541.00480-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7983252/
https://www.ncbi.nlm.nih.gov/pubmed/33778055
http://dx.doi.org/10.1183/23120541.00480-2020

Ejemplares similares